Purple Biotech Advances Immuno-Oncology Pipeline; IM1240 to Clinic 2027

Purple Biotech presented its corporate overview in June 2026, detailing its CAPTN-3 tri-specific antibody platform for immuno-oncology. The company's lead program, IM1240, a first-in-class tri-specific antibody, is slated to begin clinical trials in 2027, with preclinical data showing significantly improved safety and potent anti-tumor activity. A second program, IM1305, is also in preclinical development. Purple Biotech reported a cash balance of $6.4 million as of March 31, 2026, providing a runway into the first half of 2027, and highlighted the substantial market potential, referencing over $1 billion deals for comparable preclinical masked T-cell engager programs.